title: Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with immunostaining.
abstract: OBJECTIVE
  The main purpose of this retrospective study was to compare cyclin E expression levels in operable breast cancer patients determined using real-time RT-PCR and immunostaining. The prognostic relevance of cyclin E was also investigated.
  
  
  METHODS
  Specimens of invasive ductal breast cancer tissues obtained from 124 women during radical mastectomy were analyzed.
  
  
  RESULTS
  Of the tumor samples, 40.3 and 59.7% showed high expression of cyclin E in RT-PCR and immunostaining, respectively. The overall agreement probability was 0.032 according to Scott's pi statistic. With a median follow-up of 55.5 months, cyclin E expression assessed using immunostaining was an independent negative prognostic factor in the node positive group (hazard ratio 3.1; 95% CI 1.0-9.2; P = 0.045). Cyclin E expression correlated with absence of steroid receptors and younger age. RT-PCR results did not predict survival in any group of patients.
  
  
  CONCLUSIONS
  Disagreement between real-time RT-PCR and immunostaining was demonstrated. Immunostaining seems to be the more reliable method for assessing cyclin E in breast cancer cells.
authors.affiliation: Department of Chemotherapy, Medical University of Lodz, 4 Paderewski Street, 93-509 Lodz, Poland. piotrpo@mp.pl
authors.forename: Piotr
authors.initials: P
authors.lastname: Potemski
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Pluciennik
authors.forename: Andrzej K
authors.initials: AK
authors.lastname: Bednarek
authors.forename: Renata
authors.initials: R
authors.lastname: Kusinska
authors.forename: Dorota
authors.initials: D
authors.lastname: Jesionek-Kupnicka
authors.forename: Grazyna
authors.initials: G
authors.lastname: Pasz-Walczak
authors.forename: Cezary
authors.initials: C
authors.lastname: Watala
authors.forename: Radzislaw
authors.initials: R
authors.lastname: Kordek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000556:secondary / Q000601:surgery / Q000628:therapy; D003131:Combined Modality Therapy; D019927:Cyclin E / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007120:Immunochemistry; D008207:Lymphatic Metastasis; D015409:Mastectomy, Radical; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
chemical_list: D019927:Cyclin E; D018719:Erb-b2 Receptor Tyrosine Kinases